Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze PLBC stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate PLBC investment potential.

What is PLBC stock price today?

Get real-time PLBC stock price, historical data, and price charts on Financhill. Track PLBC performance with our advanced analysis tools.

Is PLBC a good investment?

Evaluate PLBC investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy PLBC stock?

To buy PLBC stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of PLBC?

View detailed market capitalization data and company valuation metrics for PLBC on our comprehensive analysis page.

What is the P/E ratio of PLBC?

Use our fundamental analysis tools to view PLBC P/E ratio and compare valuation metrics with industry peers.

What are PLBC earnings?

View PLBC earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Plumas Bancorp 10K Form

Buy

PLBC
Plumas Bancorp

Last Price:

$45.55

Seasonality Move:

4.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-07	10Q	PLBC/Plumas Bancorp Quarterly
2023-11-08	10Q	PLBC/Plumas Bancorp Quarterly
2023-08-09	10Q	PLBC/Plumas Bancorp Quarterly
2023-05-03	10Q	PLBC/Plumas Bancorp Quarterly
2022-11-09	10Q	PLBC/Plumas Bancorp Quarterly
2022-08-04	10Q	PLBC/Plumas Bancorp Quarterly

Receive PLBC News And Ratings

See the #1 stock for the next 7 days that we like better than PLBC

PLBC Financial Statistics

Sales & Book Value

Annual Sales:	$73.3M
Cash Flow:	$5.6M
Price / Cash Flow:	12.23
Annual Sales:	$35.38
Price / Book:	1.29

Profitability

EPS (TTM):	4.27330
Net Income (TTM):	$26.4M
Gross Margin:	$0
Return on Equity:	13.38%
Return on Assets:	1.5%

Plumas Bancorp Earnings Forecast

Key Plumas Bancorp Financial Ratios

The Gross Profit Margin over the past 27 years for PLBC is 0.00%.
The Selling, General & Administrative Expenses for PLBC have been equal to 0.00% of Gross Profit Margin.
The Interest Expense is 16.34% of Operating Income.
The Net Earning history of PLBC is 39.07% of Total Revenues.
Per Share Earnings over the last 27 years have been positive in 20 years.

Plumas Bancorp Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Banks
Sector:	Financials
Current Symbol:	PLBC
CUSIP:	729273
Website:	plumasbank.com

Debt

Debt-to-Equity Ratio:	0.59
Current Ratio:	0.06
Quick Ratio:	0

Price-to-Earnings

Trailing P/E Ratio:	9.5
Forward P/E Ratio:	8.49

PLBC Technical Analysis vs Fundamental Analysis

Buy

Plumas Bancorp (PLBC) is a Buy

Is Plumas Bancorp a Buy or a Sell?

Plumas Bancorp stock is rated a Buy

The current Plumas Bancorp [PLBC] share price is $45.56. The Score for PLBC is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.